Growth hormone treatment reduces peripheral thyroid hormone action in girls with Turner syndrome

SUSPERREGUY S, ; MIRAS MB; MONTESINOS MM; MASCANFRONI ID; MUÑOZ L; SOBRERO G; SILVANO L; MASINI - REPISO AM; COLEONI AH; TARGOVNIK HM; PELLIZAS CG

Blackwell Publishing

Lugar: Oxford; Año: 2007 vol. 67 p. 629 - 629

font size="3" face="ArialMT"> Objective: Turner Syndrome (TS) is an indication for growth hormone (GH) therapy in spite of the modest growth response. Somatic growth depends not only on GH-insulin like growth factor I (IGF-I) axis but also on thyroid hormone (TH) status. We have previously reported that supraphysiological IGF-I levels diminished TH actions in rat tissues by reducing nuclear TH receptor (TR). GH treatment to TS patients induces high IGF-I levels and therefore a reduction of TH action in tissues may be expected. We aimed at evaluating the effect of GH therapy to TS girls on peripheral TH action. Design and patients: We set up a RT-PCR for TR mRNA estimation in peripheral blood mononuclear cells (PBMC) and compared TR mRNA levels from 10 normal, 10 TS and 10 TS girls u